Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman's individual risk of disease
Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman's individual risk of disease
Aims/hypothesis: the cost-effectiveness of eight strategies for screening for gestational diabetes (including no screening) was estimated with respect to the level of individual patient risk.
Methods: cost–utility analysis using a decision analytic model populated with efficacy evidence pooled from recent randomised controlled trials, from the funding perspective of the National Health Service in England and Wales. Seven screening strategies using various combinations of screening and diagnostic tests were tested in addition to no screening. The primary outcome measure was the incremental cost per quality-adjusted life-year (QALY) over a lifetime.
Results: the strategy that has the greatest likelihood of being cost-effective is dependent on the risk of gestational diabetes mellitus for each individual woman. When gestational diabetes mellitus risk is <1% then the no screening/treatment strategy is cost-effective; where risk is between 1.0% and 4.2% fasting plasma glucose followed by OGTT is most likely to be cost-effective; and where risk is >4.2%, universal OGTT is most likely to be cost-effective. However, acceptability of the test alters the most cost-effective strategy.
Conclusions/interpretation: screening for gestational diabetes can be cost-effective. The best strategy is dependent on the underlying risk of each individual and the acceptability of the tests used. The current study suggests that if a woman’s individual risk of gestational diabetes could be accurately predicted, then healthcare resource allocation could be improved by providing an individualised screening strategy
cost effectiveness, gestational diabetes, screening, risk factors, cost–utility
256-263
Round, J.A.
03ac2237-84dd-4308-8b1d-26be17fc9974
Jacklin, P.
7068203f-3728-47c8-adfd-dcab47d27974
Fraser, R.B.
00626928-0810-431f-a573-ebbf5e9b8aa0
Hughes, R.G.
116d9141-96f5-422d-85a5-3b36240d5c0c
Mugglestone, M.A.
23edad94-6571-47d0-8164-3b5ed11b2c16
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
February 2011
Round, J.A.
03ac2237-84dd-4308-8b1d-26be17fc9974
Jacklin, P.
7068203f-3728-47c8-adfd-dcab47d27974
Fraser, R.B.
00626928-0810-431f-a573-ebbf5e9b8aa0
Hughes, R.G.
116d9141-96f5-422d-85a5-3b36240d5c0c
Mugglestone, M.A.
23edad94-6571-47d0-8164-3b5ed11b2c16
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
Round, J.A., Jacklin, P., Fraser, R.B., Hughes, R.G., Mugglestone, M.A. and Holt, R.I.G.
(2011)
Screening for gestational diabetes mellitus: cost-utility of different screening strategies based on a woman's individual risk of disease.
Diabetologia, 54 (2), .
(doi:10.1007/s00125-010-1881-y).
(PMID:20809381)
Abstract
Aims/hypothesis: the cost-effectiveness of eight strategies for screening for gestational diabetes (including no screening) was estimated with respect to the level of individual patient risk.
Methods: cost–utility analysis using a decision analytic model populated with efficacy evidence pooled from recent randomised controlled trials, from the funding perspective of the National Health Service in England and Wales. Seven screening strategies using various combinations of screening and diagnostic tests were tested in addition to no screening. The primary outcome measure was the incremental cost per quality-adjusted life-year (QALY) over a lifetime.
Results: the strategy that has the greatest likelihood of being cost-effective is dependent on the risk of gestational diabetes mellitus for each individual woman. When gestational diabetes mellitus risk is <1% then the no screening/treatment strategy is cost-effective; where risk is between 1.0% and 4.2% fasting plasma glucose followed by OGTT is most likely to be cost-effective; and where risk is >4.2%, universal OGTT is most likely to be cost-effective. However, acceptability of the test alters the most cost-effective strategy.
Conclusions/interpretation: screening for gestational diabetes can be cost-effective. The best strategy is dependent on the underlying risk of each individual and the acceptability of the tests used. The current study suggests that if a woman’s individual risk of gestational diabetes could be accurately predicted, then healthcare resource allocation could be improved by providing an individualised screening strategy
This record has no associated files available for download.
More information
Published date: February 2011
Keywords:
cost effectiveness, gestational diabetes, screening, risk factors, cost–utility
Organisations:
Dev Origins of Health & Disease
Identifiers
Local EPrints ID: 166041
URI: http://eprints.soton.ac.uk/id/eprint/166041
ISSN: 0012-186X
PURE UUID: 2c56ffd8-d84c-4c4d-ab53-4d9076999fa1
Catalogue record
Date deposited: 21 Oct 2010 13:17
Last modified: 14 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
J.A. Round
Author:
P. Jacklin
Author:
R.B. Fraser
Author:
R.G. Hughes
Author:
M.A. Mugglestone
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics